FDA Seeks to Advance Treatments for Opioid Use Disorder

Article

The agency has released new guidance on the development of new medication-assisted treatments for opioid dependence.

On April 20, 2018, FDA published draft guidance on the development of new medication-assisted treatments for opioid dependence. This first of two guidance documents is part of the agency’s action to encourage innovation in the development of opioid addiction treatments.

The new draft guidance, Opioid Dependence: Developing Depot Buprenorphine Products for Treatment, discusses drug development and trial design issues relevant to the study of depot buprenorphine products (i.e., modified-release products for injection or implantation), for which submission of a new drug application (NDA) through the pathway described in section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) may be appropriate. In the guidance, the agency addresses development plans, including studies to support approval and efficacy trials.

“Today’s action by FDA reflects the Trump Administration’s commitment to bringing the best science we have to bear in the fight against opioid addiction. We know medication-assisted treatment is effective in treating addiction, and we at the Department of Health and Human Services are using every avenue we have to boost access to it,” said HHS Secretary Alex Azar in a press release. “FDA Commissioner Scott Gottlieb has made advancing medication-assisted treatment a priority at FDA in particular, and we believe this new guidance can help accelerate the pathway for developing new drugs and new formulations of existing drugs.”

“These new guidance documents may ultimately lead to new treatments that improve outcomes for those struggling with an opioid addiction … In addition, in the coming months, we will take additional steps, beyond these guidance documents, to help promote the development of better treatments for those suffering from opioid use disorder,” Commissioner Gottlieb said in a statement.

Source: FDA

 

Recent Videos
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Kate Coleman, vice president regulatory affairs, quality and compliance, Arriello, chats about industry trends and technological advances.
Industry Outlook 2025: The Rising Prominence of AI in Pharma
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
Related Content
© 2025 MJH Life Sciences

All rights reserved.